ω-Conotoxin GVIA mimetics that bind and inhibit neuronal Ca(v)2.2 ion channels.

Charlotte Elisabet Tranberg, Aijun Yang, Irina Vetter, Jeffrey R McArthur, Jonathan B Baell, Richard J Lewis, Kellie L Tuck, Peter J Duggan

Journal: Marine drugs 2013;10(10):2349-2368

PMID: 23170089

Abstract

The neuronal voltage-gated N-type calcium channel (Ca(v)2.2) is a validated target for the treatment of neuropathic pain. A small library of anthranilamide-derived ω-Conotoxin GVIA mimetics bearing the diphenylmethylpiperazine moiety were prepared and tested using three experimental measures of calcium channel blockade. These consisted of a ¹²⁵I-ω-conotoxin GVIA displacement assay, a fluorescence-based calcium response assay with SH-SY5Y neuroblastoma cells, and a whole-cell patch clamp electrophysiology assay with HEK293 cells stably expressing human Ca(v)2.2 channels. A subset of compounds were active in all three assays. This is the first time that compounds designed to be mimics of ω-conotoxin GVIA and found to be active in the ¹²⁵I-ω-conotoxin GVIA displacement assay have also been shown to block functional ion channels in a dose-dependent manner.

Address: CSIRO Materials Science and Engineering, Bag 10, Clayton South, Victoria 3169, Australia.; Institute for Molecular Bioscience, The University of Queensland, St Lucia, QLD 4072, Australia.; Health Innovations Research Institute, RMIT University, Melbourne, Victoria 3083, Australia.; Medicinal Chemistry and Drug Action, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.; School of Chemistry, Monash University, Clayton, Victoria 3800, Australia.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.